QDEL · QuidelOrtho Corporation · Stock research

7# QDEL — QuidelOrtho Corporation

Current Thesis

Nothing has been signed and nothing further has broken. The 2026-08-06 print cut FY2026 revenue guidance to $2.52–2.60B from $2.70–2.75B, adjusted EPS to $0.65–0.90 from $1.80–2.00, and withdrew the $100–120M free-cash-flow guide; shares fell 21.3% in the session and closed $13.75 on 2026-08-10, back at the $13.79 close of 2026-06-26 that preceded the FT/Bloomberg divestiture reports. Since then the tape has drifted to $14.30 on 2026-08-14 and $14.74 on 2026-08-21 with no new company disclosure behind it — the aggregator flow since mid-August carries only re-syndication of the 2026-08-06 release. What an investor is underwriting at this level is an unsigned point-of-care divestiture, reported on 2026-06-27 at a ~$1.5B valuation, against $2.87B of total debt, $123M of cash and 4.3x net leverage, with a China lab business that fell 23% YoY in Q2.

The narrative is dead. The specific leg — a near-term $1.5B sale re-rating a levered equity — failed on its own terms. The 35% gap of 2026-06-29 was fully retraced by 2026-08-10, management declined to confirm the process on the 2026-08-06 call, and the earnings guide was reset roughly 60% lower on adjusted EPS in the same release. The two weeks since have added price and no information. A signed agreement would open a new leg; it would not resume this one.

Bullish and bearish views on QuidelOrtho Corporation

The model's bull view on QuidelOrtho Corporation (QDEL), in brief: Cost-out is landing while the top line shrinks. The bear view: China deteriorated faster than the model. Both cases follow in full.

Bull Case

• Cost-out is landing while the top line shrinks. Q2 2026 adjusted EBITDA $129M, +21% YoY, margin 20% with ~310bps of expansion (2026-08-06 release).
• The quarter itself beat. Revenue $630.9M vs $618.8M consensus and adjusted EPS $0.13 vs a $(0.05) estimate; the damage came from the forward guide, not the printed period.
• The equity is a thin claim on a large asset. 68.58M shares outstanding and roughly $1.01B of market capitalisation as of 2026-08-21 (stockanalysis.com) sit against a point-of-care unit reported at ~$1.5B on 2026-06-27, with Advent International, SK Capital Partners and Archimed named as interested. A signature near that headline resets the capital structure in one step.
• Management left the door open on 2026-08-06. Asked directly, CEO Brian Blaser said the company does not comment on market rumors, then added that it regularly evaluates a broad range of opportunities including portfolio opportunities.
• The reset guide was set with post-quarter order data in hand. The ~2026-11-04 (est.) Q3 print is the first measurement against numbers management chose after seeing Chinese destocking, rather than against pre-season assumptions.

Bear Case

• China deteriorated faster than the model. Q2 China revenue -23% YoY. The June 2026 second draft of the Chinese IVD pricing guideline removed use-case differentiation, broadened product scope, and expanded the pilot from three provinces to six; management said customers were adjusting purchasing and inventory "more quickly and significantly than we had anticipated" (2026-08-06 call).
• Withdrawing free-cash-flow guidance at 4.3x net leverage is the heaviest line in the release. $2.87B of total debt against $123M of cash as of 2026-08-06 leaves the equity as the residual tranche.
• Guidance has been reset twice inside one fiscal year, ending at a $0.65–0.90 adjusted EPS range versus $1.80–2.00 previously — a credibility discount that a single in-line quarter does not clear.
• The prior-year comparison is a $1.13B FY2025 net loss (EPS -$17.81) including a $701M non-cash goodwill impairment taken in Q3 2025 against the 2022 Ortho Clinical combination.
• Sell-side dispersion is wide and the high end is stale. JPMorgan cut to $11 with an Underweight rating on 2026-08-07, ~25% below the 2026-08-21 close of $14.74; Citigroup's $18 Neutral target dates from 2026-07-08 and predates the guidance cut.
• An issuance mechanism is already on file. S-3ASR automatic shelf filed 2026-07-17 covering 1,000,000 shares (inducement/ESOP-related).

Setup & Price Structure

• Reference close $14.74 on 2026-08-21, 58.3% below the $35.38 52-week high, RSI(14) 37.6. The 52-week range is $9.92–$35.38.
• The round trip in closes: $13.79 on 2026-06-26 → a 35% gap on 2026-06-29 → $17.38 on 2026-07-17 → $13.75 on 2026-08-10 → $14.30 on 2026-08-14 → $14.74 on 2026-08-21. The retracement is complete; the drift since 2026-08-10 is roughly 7% and carries no disclosure.
• The shares are up 24.3% over three months. That figure is measured from a late-May level underneath the June gap, so it describes the rumor spike rather than any trend now in force.
• Two weeks of closes between $13.75 and $14.74 following a 21.3% down day is too short a sample to call a base. The $13.75 close of 2026-08-10 and the $13.79 pre-rumor mark form the only shelf the tape has defended since the cut.
• Crowding observables, stated as observed: no earnings date falls inside 30 days; RSI below 40 with price 58% under the high shows no momentum extension; the dated headline flow has thinned to one primary broker action since the print (JPMorgan, 2026-08-07) with post-2026-08-14 items being restatements of the Q2 release. The identifiable supply-side items are the 2026-07-17 shelf and the 356,555-RSU inducement grant to CFO Micah Young effective 2026-07-06; neither is an open-market insider sale.

Catalyst Calendar (next 30 days)

• 2026-08-23 to 2026-09-22 — no scheduled company event. As of 2026-08-21 no Q3 2026 reporting date has been announced.
• Unscheduled (second draft dated June 2026) — final Chinese IVD pricing guideline. Determines whether the Q2 destocking is a one-time reset or a permanent step-down in the lab consumables base.
• ~2026-11-04 (est.) — Q3 2026 results. Outside the 30-day window; extrapolated from the 2026-08-06 Q2 print and the 2025-11-05 Q3 2025 date, not confirmed by the company.

Elapsed catalysts

• Unscheduled (unsigned as of 2026-08-06) — definitive agreement for the point-of-care testing unit. Reported at ~$1.5B on 2026-06-27; the only identified path to materially reducing $2.87B of debt. (passed 20d ago)

What Would Change Our Mind

The residual case rests entirely on a process no one has confirmed, so it can end without a price move at all: reporting that Advent, SK Capital or Archimed have withdrawn, a signed deal well below the ~$1.5B headline with earnouts or contingent consideration, or an equity takedown off the 2026-07-17 shelf would each remove the reason to hold the name through a 4.3x-levered balance sheet. On the tape, a weekly close below $13.75 gives back the whole 2026-06-29 gap and restores the pre-rumor downtrend, with the $9.92 52-week low as the next reference. In the other direction, the case would have to be re-opened on evidence rather than price: a signed agreement at or near ~$1.5B, or a Q3 print in which China declines by materially less than the 23% YoY posted in Q2 and the withdrawn free-cash-flow forecast is reinstated. Absent one of those, the ~2026-11-04 (est.) print is the next dated information and the intervening weeks are unpriced drift.

Correlation Notes

• The two largest 2026 moves were company-specific: the 35% advance of 2026-06-29 came on M&A reporting (that session's Benzinga movers list ran alongside a Dow up 350 points), and the 21.3% decline followed the 2026-08-06 guidance cut. Index beta explains little of either.
• Shared factor with IVD peers carrying Chinese lab exposure: any final volume-based-procurement pricing rule reprices the group's consumables annuity, and the June 2026 draft already expanded the pilot from three provinces to six.
• Respiratory-season seasonality links the point-of-care line to other rapid-testing franchises; a second soft season would show up across that cohort, not in QDEL alone.
• With $2.87B of debt at 4.3x adjusted EBITDA and no free-cash-flow forecast, the equity behaves as a levered stub — more sensitive to high-yield spread moves and refinancing conditions than a typical medtech name of comparable market capitalisation.